CGEM vs LIN · $830.3M cap vs P/E 34, rev $33.99B
Cullinan Oncology LLC (CGEM) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Cullinan Oncology LLC (CGEM) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported CGEM revenue for 2022-12-31 was $0. Net income was $109.2M. CGEM currently screens at market cap $830.3M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
CGEM currently screens at market cap $830.3M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the CGEM and LIN stock pages for the full models.
Not investment advice.